VivoSeq
Ophthalmology

Retinal Detachment

12

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Retinal Detachment is an emerging landscape with 12 programs across 9 companies. The most active players are Merck & Co., Glaxo Dba Glaxosmithkline, AbbVie. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

73/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1O

ONL Therapeutics

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

11 of 13 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody215%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed11 · 65%
Terminated3 · 18%
Withdrawn1 · 6%
Unknown status1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Corneal Endothelial Cell Changes In Silicon Filled Eye
Active, not recruiting·MMinia University·N/A·NCT07418606·40 enrolled
Ranibizumab for Diabetic Traction Retinal Detachment
Completed·UUniversity of Sao Paulo·Phase 2·NCT01201161·19 enrolled
Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Completed·IIran University of Medical Sciences·Phase 1·NCT00548197·40 enrolled
Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)
Completed·UUniversity of Sao Paulo·Phase 2·NCT00690768·20 enrolled
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
Completed·—·N/A·NCT01860586·20 enrolled
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
Completed·OONL Therapeutics·Phase 2·NCT05730218·136 enrolled
Bevacizumab Against Recurrent Retinal Detachment
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT02192970·101 enrolled
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.
Completed·UUniversitätsklinikum Köln·Phase 3·NCT02834559·326 enrolled
Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment
Completed·—·N/A·NCT06166914·42 enrolled
A Study in Subjects With Retinal Detachment
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00210067·14 enrolled
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
Completed·—·Phase 1·NCT04082962·10 enrolled
Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment
Completed·—·Phase 2/3·NCT05031143·6 enrolled
Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment
Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT02068625·23 enrolled
Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment
Terminated·MMidwest Eye Institute·Phase 4·NCT04464629·7 enrolled
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT06056596·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)